 The settlement payment will be funded entirely by the Companys insurers. The previously disclosed class-action lawsuit alleged that the Company and certain of its current and former officers and directors violated the Securities Exchange Act of 1934 in connection with certain public statements made between August 30, 2011 and November 6, 2014, regarding the safety and efficacy of MacrilenTM macimorelin and the prospects for the approval of the Companys New Drug Application for the product by the FDA. 